No abstract

This study establishes that allogeneic BCT results in quicker hematologic recovery but is associated with a higher occurrence of chronic graft-versus-host disease.

The Intergroupe Francophone du My-é lome (IFM) initiated 2 trials in 1999 to study patients with high-risk (␤2-microglobulin level greater than 3 mg/L and chromosome 13 deletion at diagnosis) de novo multiple myeloma. In both protocols, the induction regimen consisted of vincristine, doxorubicin, and dexamethasone

No abstract

With the capability to significantly preserve the normal brain from radiation-induced toxicities without compromising the efficacy of tumor treatments, irradiation at ultra-high dose rate referred as FLASH-RT provides a genuine therapeutic gain. Here we focus on the current shift towards hypofractionation in clinical practice and demonstrate that such an approach significantly maximizes the benefits of FLASH-RT in an orthotopic mouse model of GBM. While the clinical implementation of FLASH-RT will require modifications to standard practice such as development of FLASH-capable accelerators as well as the adaptation of treatment regimens, there are many potential benefits including: 1) an improved management of radiation resistant tumors for which dose escalation is necessary; 2) an enhanced quality of life of cancer survivors by preventing debilitating side effects; 3) minimized complications associated with organ motion and 4) an alleviated workload and reduced cost of cancer treatments.